You have 9 free searches left this month | for more free features.

Teclistamab

Showing 1 - 20 of 20

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multiple Myeloma Trial (Teclistamab, Tocilizumab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jul 24, 2023

Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

Not yet recruiting
  • Multiple Myeloma
  • Teclistamab
  • +2 more
  • Miami, Florida
    University of Miami
Oct 20, 2023

Myeloma Multiple Trial (Off Drug Surveillance)

Not yet recruiting
  • Myeloma Multiple
  • Off Drug Surveillance
  • (no location specified)
Jun 27, 2023

Multiple Myeloma Trial (Bone marrow sampling)

Not yet recruiting
  • Multiple Myeloma
  • Bone marrow sampling
  • (no location specified)
Jul 11, 2023

Multiple Myeloma Trial (Teclistamab, Daratumumab, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Teclistamab
  • +2 more
  • (no location specified)
Oct 6, 2022

Relapsed or Refractory Multiple Myeloma Trial in Dummy (Teclistamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • Teclistamab
  • Dummy, France
  • +2 more
Aug 10, 2022

Multiple Myeloma Trial in Germany (Teclistamab (Tec), Daratumumab, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Teclistamab (Tec)
  • +4 more
  • Berlin, Germany
  • +8 more
Jan 19, 2023

High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)

Not yet recruiting
  • High-Risk de Novo Multiple Myeloma
  • Badalona, Spain
  • +9 more
Apr 27, 2023

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Recruiting
  • Multiple Myeloma
    • Annecy, France
    • +19 more
    Sep 28, 2023

    Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, Daratumumab)

    Recruiting
    • Multiple Myeloma
    • Edmonton, Alberta, Canada
    • +12 more
    Jan 27, 2023

    Multiple Myeloma Trial in Worldwide (Teclistamab, Daratumumab, Pomalidomide)

    Active, not recruiting
    • Multiple Myeloma
    • Teclistamab
    • +5 more
    • Birmingham, Alabama
    • +26 more
    Jan 17, 2023

    Multiple Myeloma Trial in Worldwide (Teclistamab, Lenalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • Melbourne, Australia
    • +13 more
    Feb 7, 2022

    High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,

    Recruiting
    • High-risk Smoldering Multiple Myeloma
    • +2 more
    • Teclistamab
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Aug 11, 2022

    Hematologic Malignancies Trial in Japan (Teclistamab)

    Recruiting
    • Hematologic Malignancies
    • Teclistamab
    • Chiba, Japan
    • +14 more
    Aug 11, 2022

    Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

    Recruiting
    • Relapsed/ Refractory Multiple Myeloma
    • Denver, Colorado
    • +19 more
    Jan 27, 2023

    Multiple Myeloma Trial (Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT

    Not yet recruiting
    • Multiple Myeloma
    • Dara-VRd intensification, Dara-R maintenance
    • +4 more
    • (no location specified)
    Dec 13, 2022

    Hematological Malignancies Trial in Worldwide (Teclistamab)

    Recruiting
    • Hematological Malignancies
    • Teclistamab
    • Birmingham, Alabama
    • +80 more
    Jan 27, 2023

    Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Teclistamab, Pomalidomide, Bortezomib)

    Recruiting
    • Relapsed or Refractory Multiple Myeloma
    • Teclistamab
    • +4 more
    • Berkeley, California
    • +188 more
    Jan 27, 2023

    Multiple Myeloma Trial in Worldwide (Daratumumab, Pomalidomide, Dexamethasone)

    Recruiting
    • Multiple Myeloma
    • Birmingham, Alabama
    • +198 more
    Jan 17, 2023

    Multiple Myeloma Trial in Worldwide (Teclistamab, Daratumumab, Lenalidomide)

    Recruiting
    • Multiple Myeloma
    • Teclistamab
    • +3 more
    • Tucson, Arizona
    • +189 more
    Jan 27, 2023